MrC's Smallcap Sweeps for Jan 2023

[MrContrarian]

Smallcap Sweep. 03-Jan-23
New Year, New Fear

Aptamer (APTA) warns FY-June may fall below market expectations, after slow H1. Guides H1 rev c.£1m due to customer delays and general economic conditions. £1 of current signed orders going into H2, "as well as contracts in negotiation and strong expressions of interest across all three business units". [SP=52 Cap=35m]
MGC Pharmaceuticals (MXC) further cost reductions: ~35% reduction in director fees; key executive officer team take 1-20% pay cut. [SP=0.6 Cap=38m]
RBG Holdings (RBGP) FD scarpers "to pursue other interests but will remain as an adviser to the Group for a short period". He is thanked. New FD appointed. [SP=65.03 Cap=61m]
Hotel Chocolat (HOTC) strategic partnership agreement with Tokyo-based Eat Creator. "Eat Creator will be providing growth capital, new supply side know-how and proven expertise in food brand development for the Japanese consume." HOTC to have 20% of JC and get 'brand royalty' rev. [SP=158 Cap=217m]
Cineworld (CINE) chaper 11 update. Will focus on selling the Group as a whole. "Any sale transaction for the Group as a whole would not include the sale of Cineworld itself." Huh? Reminds that there is no guarantee of any recovery for shareholders. [SP=3.64 Cap=50m]
Bidstack (BIDS) co suing client Azerion for payment. Azerion has sent a notice of termination. "Bidstack has improving visibility of FY23 revenue and the Board is pleased with the Company's significant commercial progress independent of the Azerion relationship." [SP=2.77 Cap=36m]
GENinCode (GENI) California state licensing approval and CLIA certification of its Irvine lab "enabling the provision of its products for the risk assessment of CVD to patients across 49 states in the United States....marks a major milestone in the commercialisation of the Company's 'first in class' polygenic CVD products CARDIO inCode". [SP=7.43 Cap=7m]
ReNeuron (RENE) CEO scarpers. She is thanked. [SP=8.79 Cap=5m]


Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 04-Jan-23
RNS stop and search

hVIVO (HVO) wins £5.2m RSV human challenge study, will be booked in 2023-4. [SP=11.7 Cap=79m]
HeiQ (HEIQ) warns FY-Dec rev $54-55m, c.20% below market expectations. Guides pretax loss $ 2.5m-3.5m. Blames China covid, world macro, high stocks at customers. Also expects FY23 below market guidance, Buys Tarn-Pur (a UK-based intellectual property company holding critical EU and UK regulatory registrations to sell elemental copper and elemental silver for use in disinfecting hygiene applications) for £850k in cash and shares. [SP=54.45 Cap=76m]
Gfinity (GFIN) Athlos Tournament Platform to be integrated into games from leading global mobile game operator, Playgendary, [SP=0.52 Cap=7m]
CyanConnode (CYAN) wins Indian order for 983k Omnimesh Modules plus metering HW and SW. No £££. [SP=14.5 Cap=35m]
Concurrent Technologies (CNC) guides FY-Dec rev c.10% ahead of market expectations (£16m) and pretax at least in line (£0.1m). Order intake over £31m. [SP=71.9 Cap=53m]
MaxCyte (MXCT) sells strategic platform license to Catamaran Bio, a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies. No £££. [SP=432.8 Cap=522m]


Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 05-Jan-23
Flogging companies

Proteome Sciences (PRM) gets milestone payment of £0.87m from licence and distributor agreement with Thermo Scientific. [SP=3.62 Cap=11m]
Angle (AGL) FY trading: "market conditions has slowed down ANGLE's commercial acceleration post FDA clearance". Rev £1m, op loss c.£22m, in line excluding closure costs for Canada. Several new orders confirmed in the first week of Jan. [SP=47.5 Cap=124m]
Live Company (LVCG) guides FY22 loss. BRICKLIVE rev flat YOY despite the reduction in tours. BRICKLIVE will look at new markets in the Middle East, not currently covered with existing partners. Plans to offer 3 K-POP events in major European cities. [SP=3.11 Cap=8m]
Seeing Machines (SEE) integration of SEEs'in-cabin monitoring system technology with the OMNIVISION (a leading global developer of semiconductor solutions) OAX4600 system-on-chip platform. "We are very confident that this will give our customers a highly optimized silicon platform that can target the driver as well as the wider interior sensing market." [SP=6.66 Cap=274m]
Checkit (CKT) wins 3 contracts worth 1m over 3 yrs. Also renewed contract worth c.£2.1m over 4 yrs. [SP=22 Cap=24m]
REACT (REAT) wins 2 yr contract to perform deep cleaning, window and façade cleaning across c.350 mainland UK locations. Worth £0.8m in FY-Sep. [SP=1.03 Cap=11m]
Galliford Try (GFRD) wins £95m contract to deliver a new prison facility, [SP=164.5 Cap=179m]

In line: MTW
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 06-Jan-23
Brisk frisk

Nanoco (NANO) a term sheet for a no fault settlement with Samsung in QLED patent claim. 30 days to agree the detailed terms. [SP=43 Cap=137m]
Omega Diagnostics (ODX) US expansion update: maiden £50k order for FoodPrint system from a CLIA certified US lab. Appoints a new US importer for FoodPrint kits. A FoodPrint test can identify unique food sensitivity reactions. [SP=3.8 Cap=9m]
One Media iP (OMIP) guides FY-Oct core biz in line with rev c.£5.1m and EBITDA c.£1.8m. Decides not to use external funding for anti-piracy SaaS subsidiary, TCAT. [SP=6.35 Cap=14m]
Quantum Blockchain Technologies (QBT) theoretical checks on the quantum computing version of the SHA-256 bitcoin algorithm being carried out before drafting patent application. [SP=1.1 Cap=11m]


Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 09-Jan-23
Line of Booty

Devolver Digital (DEVO) guides FY-Dec rev in line but adj EBITDA $20m to $22m, below expectations (whose?). Also write downs of capitalised development costs, and acquisition IP and goodwill. Outlook "negative global economic outlook and reduction in consumer spending to continue into 2023, which may affect sales volume" [SP=65 Cap=278m]
Induction Healthcare (INHC) CEO resigns, becomes adviser. "Board is clear on the need to tightly manage costs and execute a plan ensuring the Group is correctly sized and on target to deliver a cash breakeven position during FY24." [SP=22 Cap=21m]
Anpario (ANP) warns FY-Dec only £33m+ and adj EBITDA £5m+. Blames CHina covid, some port shipping delays. Customers tightening belts. Outlook: "encouraged by the improvement in our gross margins in recent months as a result of our actions to increase sales prices and are experiencing an easing of raw material price inflation, both of which are helping the Group to rebuild its margin". [SP=462 Cap=114m]
Nanoco (NANO) more on mooted settlement of litigation with Samsung. "Gross settlement value should be expected to be towards the lower end of the range of expectations for a successful jury trial outcome...likely to be a one off payment." [SP=56.11 Cap=181m]
Kromek (KMK) repeat order, worth $0.8m, from a US government customer for its D3S ID wearable nuclear radiation detector. [SP=10 Cap=44m]
BATM Advanced Communications (BVC) $26m government cyber security order, to be delivered over 5 yr max. [SP=31 Cap=137m]
DeepVerge (DVRG) guides FY22 rev c.£17.2m, slightly below market expectations. Restructuring expected to deliver considerable cost savings in 2023 of up to £2m. [SP=1.9 Cap=14m]
Kazera (KZG) further payment from Hebei Xinjian Construction of c. $716k. A further $1.9m is expected to be paid by Xinjian by the end of Jan. [SP=0.85 Cap=9m]
Venture Life (VLG) licensing of an internally developed oral care range to an existing long term customer and that it has signed a further distribution agreements for Gelclair & Pomi-T. [SP=34.22 Cap=44m]
Iofina (IOF) guides production of 282MT vs f/c 255-275MT. Iodine spot price moved from $50/Kg at the start of the year and remained at approximately $70/Kg towards the end of 2022. [SP=22.64 Cap=42m]
Poolbeg Pharma (POLB) initial trial analysis shows POLB 001 "demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo". [SP=7.3 Cap=37m]
Renalytix (RENX) agreement with U.S. Veterans Health Administration to install the KidneyIntelX solution inside their Cloud Infrastructure and interface it with the VA Electronic Health Record Systems.Will be implemented on a phased basis over c. 18-months. [SP=94.9 Cap=82m]
N Brown (BWNG) settles ongoing legal dispute with Allianz Insurance re claim issued against subsidiary JD Williams. Latter will pay the Insurer £49.5m. Insurer claimed over £70m. Co has sufficient liquidity to pay. [SP=26 Cap=117m]

In line: MEX, OSI
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 10-Jan-23
Top of the Flops

Hostmore (MORE) FY-Jan trading. H2 rev down 14% on FY19. In line? CEO scarpers. He is thanked. Internal promotion t CEO. [SP=14.02 Cap=18m]
Marks Electrical (MRK) guides Q1-3 rev up 22%. Q3 rev up 33%. Sounds in line.; [SP=90 Cap=94m]
Gresham Technologies (GHT) guides FY-Dec rev and profit slightly ahead of recently upgraded market expectations (rev £48.5m, adj EBITDA £10.1m). "We now have very good visibility across both Clareti and non-Clareti with over £42 million of 2023 Group revenues already under contract." [SP=176 Cap=147m]
WANdisco (WAND) wins $6.6m contract with global telco. [SP=899.45 Cap=593m]
ADVFN (AFN) FCA approves Amit Tauman, together with his father Yair Tauman, holding up to 29.9%. [SP=34 Cap=16m]
Nanosynth (NNN) £0.4m placing at 0.18p to keep the lights on. Doesn't mention the 35% discount. [SP=0.3 Cap=7m]
Sancus Lending (LEND) cuts offices from 5 to 3. Will cease new business activities in Gibraltar due to insufficient quality lending opportunities. CFO will leave. She is thanked. [SP=1.5 Cap=16m]
Robert Walters (RWA) warns FY-Dec profit lightly below market expectations due to global macro. Net fee income up 20%. [SP=550 Cap=412m]
Churchill China (CHH) guides FY-Dec pretax at the upper end of analyst expectations of £8m to £8.8m.. [SP=1227 Cap=135m]
Smiths Mews (SNWS) renews Telegraph contract. [SP=55 Cap=136m]
Zenova (ZED) sub-distributor in the USA, Omnis, has placed an initial order for 7,500 FX500 mini fire extinguishers. [SP=10.98 Cap=10m]
AO World (AO.) guides FY-Mar adj EBITDA £30m to £40m cf previous guidance £20m to £30m. [SP=69.6 Cap=402m]
Card Factory (CARD) guides FY-Jan EBITDA at least £106m and pretax c. £48m+, ahead of expectations (|whose?) [SP=87.2 Cap=299m]
Hornby (HRN) Q1-3 rev up 6%, behind budget due to the challenging consumer economic climate. Guides FY modest underlying loss before tax. [SP=29 Cap=49m]
Tekmar (TGP) wins contracts worth £10m. [SP=13.33 Cap=8m]
Gulf Marine Services (GMS) guides FY-Dec EBITDA $70-72m, in line and FY23 $75-83m. Latter "driven predominately by a combination of higher utilization levels (expected to increase from 88% to 93%) and increase in day rates (expected to increase by 8% across the fleet)". [SP=4.76 Cap=46m]
Eden Research (EDEN) guides FY22 rev up 50%, pretax loss c. £2.8m both better than mkt exp of £1.7m and £3.1m resp. [SP=4.49 Cap=17m]
Trackwise Designs (TWD) trading resumes. [SP=1.18 Cap=2m]

In line: SOS, SHI, SUP
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 11-Jan-23
Have I Got Views For You

Surface Transforms (SCE) dabs the brakes as it warns FY-Dec rev up 113%, less than previously guided. Blames production probs in Nov and Dec as volumes were ramped up. "The problem furnaces are now operational but management wish to see several weeks of consistent output before being comfortable to confirm that the issue has been permanently resolved." FY23 production guidance unchanged. [SP=38 Cap=91m]
Reach (RCH) warns Q4 rev miss at 4.2% down due to weak ad rev: "significantly lower than anticipated benefit from traditionally stronger programmatic yields and campaign spend around Black Friday and Christmas, which has affected the whole sector." Guides FY-Dec op profit below market consensus (£112.8m) by mid-single digits %. [SP=109.51 Cap=347m]
Argo Blockchain (ARB) more bad news as Dec mining only 147 Bitcoin equiv (Nov:198) dur to electricity rationing in Texas during storms. [SP=10.65 Cap=61m]
Cornerstone FS (CSFS) guides FY-Dec rev up 109%, 12% ahead of market expectations. Gross margin c.61% (52%). [SP=5.76 Cap=3m]
Nichols (NICL) guides FY-Dec rev up 14%. Adj pretax in line with market expectations. Guides FY23 FY23 adj pretax broadly in line with FY22 "but remains confident of significant progress in FY24 as inflationary pressures abate". [SP=1100 Cap=401m]
WANdisco (WAND) giodes FY-Dec rev up 229%. In line? Loss? Outlook: "As the Group progressed through 2022, the breadth and depth of the pipeline continued to strengthen. This combined with the expectation of a significant ramp-up of consumption under the agreements signed in 2022 places the Group in a strong position as we enter 2023". [SP=902 Cap=600m]
Warpaint London (W7L) guides FY-Dec c.£64m vs guided £61m+. Adj pretax c. £10m, ahead of market expectations and mgmt guidance of £9m+. [SP=188 Cap=144m]
Lookers (LOOK) guides FY-Dec U/L pretax £80m+, ahead of mgmt exp. FY23 exp remain unchanged. [SP=77.9 Cap=301m]
Ten Entertainment (TEG) guides FY-Jan rev up 88% and adj pretax at upper end of market expectations of £25-26.1m. [SP=290 Cap=199m]
Physiomics (PYC) further contract with Cancer Research, expected to be completed during Q1 2023. [SP=4.68 Cap=5m]
M Winkworth (WINK) guides FY-Dec pretax modestly ahead of market forecast of £2.3m. "We are very pleased with our sales results for last year and are less downbeat than the consensus on the outlook for prices in the current one. Lettings market activity abated towards the end of 2022, but we expect it to be strong again in 2023." [SP=155 Cap=20m]

In line: JSG, CREO, NGHT, QTX, HSW, ABDP, TPT
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 16-Jan-23
It Ain't Half Shot Mum

Amigo (AMGO) unable to secure a commitment from a cornerstone investor to underwrite the whole of the capital raise. "A number of investors have expressed possible interest in making a minority investment. Amigo is therefore assessing whether there is sufficient interest for a syndicate of such investors to be formed in order to support a £45m Capital Raise." Will wind-up co if unable to succeed. [SP=3.9 Cap=19m]
MJ Hudson (MJH) confirms indications of interest for certain divisions of the business. Trading weak. [SP=13 Cap=27m]
Spectral MD (SMD) guides FY-Dec rev above mkt exp, EBITDA loss and cash materially ahead. Cites strong execution of Burn clinical studies and related development activities as well as the expansion of the current BARDA contract. [SP=31.3 Cap=43m]
Ashtead Technology (AT.) guides FY-Dec rev up c.30% and adj EBITDA modestly ahead of mkt exp. [SP=334.68 Cap=266m]
Invinity Energy Systems (IES) MoU with Dawsongroup to develop UK battery rental offering.Dawsongroup has purchased a 0.22 MWh Invinity VS3 as a demonstrator. [SP=39 Cap=46m]
Totally (TLY) wins £10m PA contract to provide national NHS 111 contingency services, initially for 1 year with a 1 yr option. [SP=35 Cap=68m]
Quixant (QXT) guides FY-Dec rev £120m, slightly ahead of market expectations (rev $115.2m and adj pretax $10.1m). Adj pretax also slightly ahead of market expectations.Order book strong. [SP=169.58 Cap=111m]
IQE (IQE) guides FY-Dec rev c. 8% up. Provisions for a small number of doubtful debts and the 're-phasing' of rev from one contract from Q4 to Q1 2023. Constant currency revenue is expected to be broadly in line. [SP=59.64 Cap=480m]
Zenova (ZED) Big Battery (USA's largest lithium battery supplier) places a first order for the FX500 mini extinguisher. Expects more substantial orders in the near future. [SP=11.5 Cap=11m]
Tekmar (TGP) a preferred partner given another 14 days for alternate debt or equity financing proposals. Does not prevent an offer being made for the Company by a third party. [SP=17 Cap=10m]
Intelligent Ultrasound (IUG) guides FY-Dec rev up 33% despite reseller markets in Europe and Asia down 19% to £1.7m, largely due to impact of Covid-19 on the Chinese market. In line? [SP=8.48 Cap=27m]
Ondo InsurTech (ONDO) contract with insurer Topdanmark to expand roll-out to 20,000 new customers in Denmark. COO says "this deal shows our commitment to roll out LeakBot across more of our customer base". [SP=6.02 Cap=4m]
Poolbeg Pharma (POLB) strategic expansion of POLB 001 into oncology. "Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies." [SP=9.55 Cap=48m]
Quadrise Fuels International (QFI) projects update. "Whilst we are frustrated with the delays that we have faced in progressing some of our projects, we remain confident that these will be overcome soon." [SP=1.7 Cap=24m]
Ilika (IKA) MoU with Cirtec Medical to collaborate in the manufacturing and commercialisation of miniature Stereax solid-state batteries. [SP=35 Cap=55m]

In line: MPAC, AVG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 17-Jan-23
Universally Challenged

Unbound (UBG) warns FY-Feb rev up only 3-4% and adj pretax -£4.25m to -£4.75m below market expectations. Cost cuts. Outlook "Despite the short-term challenges experienced, the Group is well positioned for an enhanced Spring / Summer product portfolio launch". Well, that's a relief. [SP=4.15 Cap=4m]
Revolution Bars (RBG) Xmas LFL down 9% on 2019 and H1 down 9.4% on 2019 as a whole. Blames hot summer, railway strikes and poor economic outlook. Guides FY IAS 17 EBITDA at the bottom end market expectations of £6.7-10.5m. [SP=5.85 Cap=13m]
Naked Wines (WINE)guides FY-Mar adjusted EBIT £13-17m (previously £9-13m). Q3 rev flat but down 6% in const currency. [SP=133.94 Cap=99m]
Corero Network Security (CNS) warns FY-Dec rev $20.1m ($20.9m), below market guidance. Blames "delays in customer decision making and buying cycles being extended". Adj EBITDA $1.4 - $1.8m. Order intake up 13%. [SP=8 Cap=40m]
Avacta (AVCT) AVA6000 phase 1: "tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential ". [SP=159.5 Cap=424m]
The Pebble Group (PEBB) guides FY-Dec at least in line with market expectations. Outlook: "Board is pleased with progress in both Facilisgroup and Brand Addition. We continue to invest significantly into the acceleration of growth in Facilisgroup". [SP=91.75 Cap=154m]
Civitas Social Housing (CSH) enforcement notice in respect of My Space issued as expected. My Space is 1.3% of rent roll and is now in arrears. [SP=59.75 Cap=362m]
Ethernity Networks (ENET) £1.55m placing at 7p, about par, to keep the lights on. Wanrns FY22 rev up only 10%. c. $600k delayed to FY23. "Rresources will be best utilised in these areas that will produce revenues and cash flows in the short and medium term...re-evaluating whether to continue the work with an Indian OEM customer which continues to experience repeated delays." [SP=7 Cap=5m]
Quiz (QUIZ) guides FY-Mar profit at least in line with its expectations after Dec rev up 11%. [SP=15.67 Cap=19m]
National World (NWOR) guides FY-Dec rev £84m+ (in line) and adj EBITDA ahead of market expectations. H2 digital rev up only 12% due to "market and audience volatility, combined with the impact of changes to Google's search algorithm". Mitigated by stronger yields and increased video advertising. Maiden div. [SP=22 Cap=57m]
Equals (EQLS) guides FY-Dec rev up 59%. adj EBITDA up 79%, ahead of market expectations. [SP=94 Cap=170m]
Kanabo (KNB) two new medical cannabis products for patients with severe pain. [SP=1.87 Cap=8m]
NIOX (NIOX) guides FY-Dec underlying revenue growth of c.15%. Adj EBITDA c. £7m, ahead of mkt expectations. [SP=43 Cap=164m]
Renold (RNO) wins 7 yr contract for £8.7m. [SP=26.92 Cap=61m]
Grand Vision Media (GMVH) knows of no commercial or operational reason for the SP rise. [SP=NA Cap=NA]

In line: APH, MGP, MCB, RPS, BOKU
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 18-Jan-23
Game of Moans

Omega Diagnostics (ODX) warns FY-Mar lower than expected revenue, Rev at Health and Nutrition business £7.5-£8m. EBITDA loss (cont) c. £1m. "With the later than anticipated receipt of customer orders, Company has insufficient manufacturing capacity to meet anticipated demand." Stronger than expected order book for FY24. [SP=3.82 Cap=9m]
STM (STM) guides FY-Dec rev £24.1m and pretax £1.7m. H2 "albeit slower than anticipated, particularly within the personal pensions and life assurance business". [SP=28.02 Cap=17m]
Fix Price (FIXP) opens two stores in Mongolia. [SP=NA Cap=NA]
Triad (TRD) H2 has seen "a strong upturn in levels of new business wins and bidding activity". In line? [SP=95 Cap=16m]
Alpha Group (ALPH) guides FY-Dec rev up 27% and pretax ahead of expectations. [SP=1863.88 Cap=798m]
Mercia Asset Management (MERC) sold Intechnica for £14.5m (EV) = £3.7m cash, 70% above book. [SP=33.45 Cap=147m]
Team17 (TM17) guides FY-Dec rev and adj EBITDA significantly ahead of market expectations. [SP=410 Cap=597m]
Crimson Tide (TIDE) guides FY-Dec rev >£5.3m up 30%, smaller than expected pretax loss due to high rev and cautious H2 marketing spend. [SP=2.51 Cap=17m]
Engage XR (EXR) guides FY-Dec rev up 63% and EBITDA loss €5.8m. In line? [SP=4.8 Cap=14m]
Tissue Regenix (TRX) distribution agreement for OrthoPure® XT in China. Distributor must purchase a minimum unit volume each year to maintain its exclusive status. [SP=0.63 Cap=44m]
Midwich (MIDW) guides FY-Dec rev up 40% and pretax comfortably ahead of market consensus of £40.8m. [SP=490 Cap=436m]
Burning Rock Biotech (BNR) hikes FY22 rev growth guidance to 10% from 5%. [SP=NA Cap=NA]

In line: EYE, SFOR, HAT, GFRD, SMRT
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 19-Jan-23
The News Squeeze

Luceco (LUCE) guides FY-Dec rev £206m and adj op profit at the upper end of the previously guided range of £20-22m. "We remain appropriately cautious about near-term prospects until the unusually wide range of macroeconomic outcomes for 2023 begins to narrow." [SP=107.1 Cap=171m]
Home REIT (HOME) won't get its audited FY out by end Jan. BDO has requested the provision of substantial data sets across what is a granular portfolio of over 2,400 properties. Appoints a specialist social housing property manager "to accelerate and further support the Investment Adviser's ongoing asset management and monitoring programme". [SP=38.7 Cap=301m]
AEW UK REIT (AEWU) Dec NAV 104.93p/sh, down from 121.88p in Sept. "Following interest rate rises and the unfolding UK macro-economic backdrop, real estate valuations across all market sectors, in particular at the prime end of the industrial and warehousing sector, fell significantly during the quarter." [SP=105.27 Cap=167m]
Zotefoams (ZTF) guides FY-Dec rev up 26%, and pretax up 70%, both ahead of market expectations. [SP=352.5 Cap=171m]
CPPGroup (CPP) guide FY-Dec rev(cont) up 19%. EBITDA c.£6.9m, above market expectations. "The Group's change management programme is a complex set of seven inter-dependent projects that is not expected to conclude before the end of the 2025 financial year. Inevitably, given the scale of the changes being implemented, there will be hiccups along the way, which in turn may lead to some adjustment to both targets and deadlines" [SP=112.4 Cap=10m]
Centaur Media (CAU) guides FY-Dec rev £41m+ and adj EBITDA margin above 19.5%. In line? 3.3p special div. [SP=47.25 Cap=69m]
ReNeuron (RENE) restructuring of the business, as expected. "Headcount has been reduced by 40%, the overall variable costs of the business lowered and, as a result, the cash runway now extends into 2024 with all resources being directed towards generating in vivo data and validating the Company's exosome delivery technology platform CustomEX". [SP=9.31 Cap=5m]
Headlam (HEAD) guides FY-Dec rev and U/L pretax marginally ahead of market expectations which are on the co's website. [SP=330.55 Cap=267m]
Capital (CAPD) guides rev $290.3m cf guided $280-290m. Profit? Outlook "drilling business has a strong outlook entering 2023 with its highest rig count, robust utilisation and strong ARPOR". [SP=114.95 Cap=218m]
Judges Scientific (JDG) guides FY-Dec rev up 8% organic. Adj EPS modestly ahead of market expectations. [SP=7900 Cap=503m]
C4X Discovery (C4XD) MALT-1 inhibitor programme: demonstrated anti-cancer activity for one of its lead molecules in a preclinical xenograft study. It positions programme for partnering. [SP=16.72 Cap=42m]
Ilika (IKA) H1-Oct rev flat at £0.2m, pretax loss £5m (£3.5m). You have to scroll a long way to see that. Headline: "Significant advancements for Stereax & Goliath, positioning the Group for commercialisation." [SP=42 Cap=66m]

In line: HOTC, KIE, AREC, BOO, STB, G4M, KOO, FIF
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 20-Jan-23
BUMP jump, Zamboni boosts word supply

Seraphine (BUMP) confirms rec 30p offer, a 206% premium. [SP=9.76 Cap=5m]
DSW Capital (DSW) warns FY-Mar rev £2.8-3.1m (£3m), EBITDA £1.4-1.7m (£2.2m). Several deal completions paused after the Truss Budget and co seeing continued deal slippage and caution in the market. [SP=118.45 Cap=25m]
Character (CCT) warns FY rev and adj pretax marginally below market expectations. Rev in last 4 months down 42%. [SP=419 Cap=81m]
Octopus Renewables Infrastructure Trust (ORIT) hikes FY-Dec 2023 target dividend to 5.79p, up 10.5%. [SP=95.27 Cap=538m]
Allergy Therapeutics (AGY) guides H1-Dec rev down 18%, "primarily due to the previously announced voluntary short-term pause in production in the UK, together with the previous strategic streamlining of some older products". Co increasingly confident that its funding discussions (as mooted) will be successful. [SP=6 Cap=42m]
Devro (DVO) guides FY-Dec rev up 15% and op profit ahead of the Board's expectations. Cites "strong operating margins, reflecting the benefits of management's pricing actions, operating efficiency and foreign exchange tailwinds." [SP=308 Cap=516m]
De La Rue (DLAR) suspends banknote printing at Kenya JV "owing to current global market demand, and no expectation of new banknote orders from the Central Bank of Kenya for at least the next year". It "further serves to adjust the capacity to current market demand, while retaining the capability to scale up operations when market demand recovers". Does not affect FY guidance. India investigation into the conduct of former Indian Finance Secretary, in which the historical activities of De La Rue in India prior to 2016 have been implicated. Co says no merit to the allegations that relate to De La Rue. Co has not served India since 2016. [SP=78.8 Cap=154m]
Circle Property (CRC) plans to return 103p/sh (initially) as it sells assets. [SP=215.1 Cap=63m]
Mirriad Advertising (MIRI) hoists For Sale flag " following the Company's progress and improved position in the US market and the development of its platform capabilities including programmatic readiness, the Company is significantly undervalued". Part of Strategic Review that may include fundraise, strategic partner or de-listing. Co has cash to Q3 2023, as stated [SP=4.1 Cap=11m]
Supply @ME Capital (SYME) long biz update. New Italian legislation when passed "is expected to provide greater opportunities for Italian banks to adopt the Platform". TradeFlow AuM up 25% over year to Dec. Zamboni claims everything's great. [SP=0.06 Cap=31m]

In line: TRU
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 23-Jan-23
Perked up or stitched up?

Surgical Innovation (SUN) guides FY-Dec rev up over 20%, ahead of market expectations. Adj EBITDA c.£0.7m, in line. Strong UK sales growth Q4 has continued into the current year, [SP=1.5 Cap=15m]
Audioboom (BOOM) guides FY-Dec rev up 25%.Adj EBITDA $3.6m up 16%. ""The challenging economic conditions in which Audioboom operated during 2022 prevented even stronger financial growth in line with our initial expectations." That's not clear to me. [SP=423 Cap=69m]
Kinovo (KINO) contract worth £4m over 2 years from the London Borough of Waltham Forest. [SP=34 Cap=21m]
Everyman Media (EMAN) guides FY-Dec rev up 63%. EBITDA up 75%, ahead of market expectations. Expects the volume and quality of new releases to significantly increase in 2023. [SP=86 Cap=78m]
TruFin (TRU) further to previous RNS, Satago is extending its agreement with Sage, adding Satago services to certain Sage 50 subscription packages in Ireland. What is Satago? [SP=57 Cap=54m]
Argo Blockchain (ARB) has regained compliance with Nasdaq rule re: SP over $1. [SP=13.9 Cap=82m]
Gulf Marine Services (GMS) contract to provide support for the construction and development of a major offshore wind farm in France, to complete in Q1 2023. [SP=4.69 Cap=47m]
DG Innovate (DGI) subscription to raise £400k at 0.12p, a 14% premium, for the commercialisation strategy for its Enhanced Drive Technology and Enhanced Battery Technology. Also a Broker Option. [SP=0.1 Cap=9m]
tinyBuild (TBLD) guides FY-Dec re in line but adj EBITDA only broadly in line (due to a greater investment in marketing). Outlook "Early indicators of positive consumer traction across the Company's diversified portfolio and pipeline are very encouraging". [SP=81.5 Cap=166m]
Sosandar (SOS) will sell a 'curated' collection of its products through Sainsbury's. Initially online only with selected stores planned later this year. [SP=21 Cap=46m]
SAGA (SAGA) confirms press report that it may sell underwriting business. [SP=150.08 Cap=211m]
Hellenic Dynamics (HELD) general update from the medical cannabis cultivator. On track for Q2 2023 revenues to meet distributor demand . Wholesale prices of medical cannabis flowers holding strong. [SP=0.12 Cap=15m]
Getech (GTC) guides FY-Dec rev £5m, ahead of market expectations. Outlook " strong balance sheet, sales pipeline growth, plus good customer and partner momentum. Getech's Board has no current plans to raise capital from shareholders." [SP=13.75 Cap=9m]
Touchstar (TST) guides FY-Dec rev up >10% and pretax doubled, both in line. Net cash generation significantly ahead. [SP=79 Cap=7m]
Dignity (DTY) warns FY-Dec rev no more than £275m, U/L pretax no more than £37m. Bid talks continue. [SP=503 Cap=252m]
Colefax (CFX) H1 in line. Guides FY ahead of expectations due to strong Dollar. [SP=630 Cap=47m]
Newmark Security (NWT) FY-Apr. Current trading "returned to profitability and positive operating cashflows during FY 2023, whilst also continuing to grow revenues. Transition to a high margin hardware enabled SaaS HCM business is continuing with a significant increase in ARR". Going concern: "reasonable expectation that co and grouphave adequate resources to continue in operational existence" [SP=40 Cap=4m]

In line: IES
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 24-Jan-23
Quantity Street

WANdisco (WAND) $9m industrial and consumer goods contract win. [SP=1055 Cap=707m]
Staffline (STAF) guides FY-Dec flat. U/L op profit marginally ahead, and cash flow substantially ahead of market expectations. [SP=33.05 Cap=55m]
NAHL (NAH) guides FY-Dec rev up 7%, pretax £0.6m ahead of market expectations "due to lower than expected profit attributable to non-controlling interests in our LLPs, offset by an increase in borrowing costs due to higher UK interest rates". [SP=34.8 Cap=16m]
Robinson (RBN) guides FY-Dec rev up 10%, 1% organic but U/L volume down 10% due to "changes in consumer behaviour, delisting of certain products by our customers and overall reduced customer demand". Adj op profit in line. Expect further property sales in Chesterfield in 2023 and 2024. [SP=93.9 Cap=15m]
FireAngel Safety Technology (FA.) guides FY-Dec rev up 32%, adj pretax -£2.1m (-£3m). Outlook confident. [SP=8 Cap=14m]
Artisanal Spirits (ART) guides FY-Dec rev up 20%, slightly ahead of consensus of £21.6m. Profit? "Continued recovery in UK member venues and events: sales now seeing the benefits of more normalised trading conditions with a record December". Outlook in line. [SP=86.5 Cap=60m]
City Pub (CPC) guides FY-Dec rev up 63%, in line. LFL up 3% on 2019. That's poor given 3 years' inflation. Outlook: Jan LFL up 25% and above expectations.. [SP=73 Cap=76m]
Deltex Medical (DEMG) guides FY-Dec rev up 10%. Cash at hand £0.5m. "Continuing to work on securing a small number of substantial orders within its International division." [SP=1.34 Cap=9m]
Henry Boot (BOOT) warns FY-Dec pretac slightly below market expectations due to year-end valuation movements in investment portfolio. Expects this FY to be more challenging. [SP=242.2 Cap=329m]
Aptamer (APTA) wins two new fee-for-service contracts initially worth over £500k. [SP=39.9 Cap=28m]
Norman Broadbent (NBB) guides FY-Dec Net Fee Income up 27% and EBITDA c.£100k (-£300k). In line? [SP=3.19 Cap=2m]
Accrol (ACRL) H1. Guides FY-Mar rev and adj EBITDA marginally ahead of expectations at £230m and £15.5m respectively. Also outcome of strategic review. Will build a paper mill. Cash cost not above £10m funded out of free cash flow, existing banking facilities and or banking finance, whichever is most appropriate at the time. Will resume dividends as soon as is practicable. [SP=29.25 Cap=93m]

In line: PEB, SAGA, SAA, BGO, ELCO, BAR, CWR, APTD, SNWS, NET
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 25-Jan-23
Big Bother

Inland Homes (INL) warns FY-Sept pretax loss c.£91m and NAV (IFRS) 40p/sh. sells greenfield "strategic land" option portfolio for £9.5m, a £3.5m profit (excludes any EPRA uplift). Obtains covenant waiver to June. "The Group has experienced an extremely disappointing year. However, we continue to see good interest for our new homes and valuable consented land in the South and South East of the UK" [SP=17.6 Cap=39m]
Home REIT (HOME) re reports of delays in the approval of exempt housing benefit applications to one of its tenants, Lotus Sanctuary CIC. Lotus has not paid any rent for the quarter to Nov. If Lotus gors bust HOME will seek to assign leases to alternative providers. [SP=38.7 Cap=301m]
Biome Technologies (BIOM) guides FY-Dec rev £6.2m, in line. Adj EBITDA in line and 'cash balance' (?) £0.8m, ahead. Outlook - substantial increase of bioplastic quantities received for delivery in Q4 and increased demand has continued. Stanelco has a much lower confirmed order book YoY. [SP=89.75 Cap=3m]
Rurelec (RUR) no improvement in Sept update with no further receipt of cash from Argentina. Cash will run out middle of Q2. Its majority shareholder rubuffed request to allow share issues. Talks to sell interest in EdS in Argentina. Co would become a cash shell if sold. [SP=0.55 Cap=3m]
RUA Life Sciences (RUA) appoints Corcym, a global medical device company focussed on the structural heart area, to bring R large bore vascular grafts to market. RUA and Corcym share the gross margin 50:50. [SP=44.7 Cap=10m]
Epwin (EPWN) guides FY-Dec rev up 8%. Adj pretax in line, cash ahead. Current trading in line. [SP=74.42 Cap=108m]
hVIVO (HVO) guides FY-Dec rev up 30%. EBITDA margin 17%+, significantly ahead of guidance of 13-15%. Will return capital. [SP=14.97 Cap=100m]
T42 IOT Tracking Solutions (TRAC) irst order of 1,000 Tetis units, from USA. No £££. [SP=5.69 Cap=3m]
discoverIE (DSCV) guides FY-Mar U/L earnings ahead of mgmt exp. [SP=786 Cap=757m]
Fonix Mobile (FNX) guides H1-Dec comfortably in line with mgmt expectations. Adj EBITDA up 12%. [SP=218 Cap=218m]
Pendragon (PDG) guides FY-Dec U/L pretax £57m, slightly ahead of market expectations. Outlook confident. [SP=19.55 Cap=273m]
eEnergy (EEAS) guides H1-Dec rev up 58% and adj EBITDA up 87% to £1.5m. Outlook is cautiously optimistic. [SP=NA Cap=NA]
Gresham House (GHE) guides FY-Dec AuM up 20%. Adj op profit over £26.5m, at the top end of market expectations, [SP=760 Cap=291m]
Lords Group Trading (LORD) guides FY-Dec rev up 24% and adj pretax at least £16m, both ahead of market expectations of £436.7m and £15.7m. Outlook "While market conditions in 2023 may become more challenging in the short term, the Group has substantial organic growth levers through new geographies and product range extension that provide our Group with the opportunity to continue its track record of growth." [SP=78 Cap=127m]

In line: XPF, OTMP, NFC
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 26-Jan-23
Sure bets and night-time sweats. A record 29 companies.

Fintel (FNTL) guides FY-Dec core rev up c.8%. Adj EBITDA up 6%, in line with mgmt exp. Outlook in line. [SP=206.75 Cap=214m]
Animalcare (ANCR) guides FY-Dec rev down 3%. U/L EBITDA approximately in line with market expectations. Blames macro. [SP=200 Cap=120m]
Renalytix (RENX) co and its partners get $10m Horizon Europe grant to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chronic kidney disease. 10% of the budget targeted for commercial translation activities to be undertaken by Renalytix. [SP=117.5 Cap=103m]
Time Out (TMO) to open Time Out Market in Barcelona in H2 2024. [SP=34 Cap=114m]
Hemogenyx Pharmaceuticals (HEMO) £4m placing at 2.5p, a 17% discount, for clinical trials and continue development of product candidates for the treatment of viral infections based on its Chimeric Bait Receptor. [SP=2.6 Cap=25m]
LSL Property Services (LSL) sells London Estate Agent Marsh & Parsons for £29m as it simplifies the group. Considering investment and shareholder distribution options. [SP=267 Cap=278m]
Ilika (IKA) to get £2.8m in grant over 2 yrs to lead Faraday Battery Challenge and to integrate high silicon content electrodes into its Goliath solid-state batteries. [SP=49 Cap=77m]
Proton Motor Power Systems (PPS) order from UMSTRO for 18 "HyModule S8" hydrogen fuel cell systems for delivery throughout 2023 and into 2024. No £££. [SP=12.49 Cap=194m]
Parity (PTY) guides FY-Dec Net Fee Income down 15% ad adj EBITDA £0.4m (£0.1m). Significant improvement in operating performance with anticipated break even adj op profit. In line? [SP=7 Cap=7m]
Learning Technologies (LTG) guides FY-Dec rev £595m+ and adj EBIT £100m+, both ahead of consensus expectations. Confident. [SP=121.72 Cap=961m]
Eurocell (ECEL) guides FY-Dec rev up 12%. U/L pretax in line. artially resolved cyber insurance claim and expect to recognise compensation over £1m. Outlook "In anticipation of weaker markets in 2023, we completed a restructuring programme in Q4 2022, which along with other cost saving measures, will reduce operating costs by approximately £5m PA from the start of 2023. A charge of c.£2m will be included as a non-underlying item in 2022". [SP=150 Cap=168m]
Empresaria (EMR) guides FY-Dec pretax in line, debt significantly better than market expectations. [SP=60 Cap=30m]
Foxtons (FOXT) guides FY-Dec rev c.£140m up 11%, ahead of market expectations. Adj op profit also ahead of market expectations. Outlook "H1 2023 to be more challenging". [SP=38 Cap=115m]
Diaceutics (DXRX) guides FY-Dec rev up 44%, materially ahead of market expectations. EBITDA in line. Exp are rev £16.3-16.8m and EBITDA £3.4-3.6m. [SP=78.05 Cap=66m]
Rotala (ROL) 55p tender offer, a 34% premium for up to 18m shares. [SP=41.75 Cap=21m]
Hansard Global (HSD) warns H1-Dec new biz down 33%. "Environment has remained challenging for investment and long-term savings plans. However, we continue to make good progress developing new product and distribution opportunities." [SP=41 Cap=56m]
Argentex (AGFX) strong, in line? [SP=132.14 Cap=150m]
Time Finance (TIME) H1. Guides FY significantly ahead of market expectations. [SP=20.5 Cap=19m]

In line: VLS, NCYT, SKL, DOTD, FLO, JUST, CTO, KETL, SPEC, AQX, BOTB
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 27-Jan-23
Winter's Fail

Superdry (SDRY) H1-Oct profit short of expectations mainly due weak Wholesale. But in the H1 trading stmt CEO said “I’m pleased with the performance of the business over the half". Adj pretax -£13.6m (-£2.8m). Cuts FY adj pretax guidance to broadly breakeven. [SP=149.2 Cap=123m]
Amigo (AMGO) not enough support for needed fundraise yet. Deadline 26 May. Return to lending - volumes have increased substantially during Jan. [SP=2.88 Cap=14m]
Motorpoint (MOTR) warns " recent reductions in finance commissions and lower gross margin, largely due to the well documented fall in electric vehicle values" will hit profit for the foreseeable future. [SP=147.5 Cap=131m]
Stelrad (SRAD) guides FY-Dec broadly in line with its expectations with rev up c.15% and 3% LFL. Adj op profit c.34m. [SP=118.3 Cap=151m]
Avon Protection (AVON) AGM stmt - sounds in line. [SP=1019.57 Cap=307m]
On the Beach (OTB) AGM stmt - Oct to date TTV up up 68%. In line? [SP=175.77 Cap=291m]
Actual Experience (ACT) FY-Sep rev in line. Outlook: advanced discussions with a large UK central government department two leading professional services firms but says sales cycles are in general lengthy. [SP=1.08 Cap=2m]

In line: TET
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 30-Jan-23
Clem Chambers' Horror Show.

Impellam (IPEL) guides FY-Dec ahead of its 'original expectations' (=current expectations?) with gross profit of £315m. Sells Regional Specialist Staffing businesses in the UK for £85m. [SP=680 Cap=306m]
Eden Research (EDEN) Mevalone has received authorisation for home garden use in Italy, the authorisation for domestic use. [SP=4.61 Cap=18m]
Sopheon (SPE) guides FY-Dec rev in line, adj EBITDA to approach $7m ($6m) comfortably exceeding market expectations. [SP=650 Cap=66m]
Online Blockchain (OBC) plans NFT project based on The Rocky Horror Show. Clem Chambers, CEO, says "I would like, if I may, to take you on a strange journey." [SP=21 Cap=3m]
DP Erasia (DPEU) guides FY-Dec rev up 77% or 13% after IAS29. Adj EBITDA ahead of current market expectations. [SP=59.6 Cap=85m]
Novacyt (NCYT) trial in dispute with Gov't to start 10 June 2024 and is expected to last 16 days. [SP=75.92 Cap=61m]
Aptamer (APTA) follow on project with multi-national consumer goods company worth up to £185k. [SP=38 Cap=26m]
RA International (RAI) wins contracts worth $8.2m [SP=12 Cap=21m]
Inspired (INSE) guides FY-Dec rev 10% ahead of market expectations at c.£88m. Adj EBITDA up 6%, in line. [SP=9.35 Cap=91m]

In line: CSH, PGH
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 31-Jan-23
Priced to fail ratio

TPXimpact (TPX) warns Q3-Dec rev below mgmtm exp "reflecting external factors largely outside the Group's control". Likely to breach covenants in March. [SP=45.45 Cap=41m]
Morses "it's not a" Club (MCL) lenders extend term-out clause to March. [SP=0.65 Cap=1m]
RBG Holdings (RBGP) CEO sacked: "The Board has lost confidence". LionFish for sale. [SP=66.03 Cap=63m]
Cambridge Cognition (COG) guides FY-Dec rev up 25%, ahead of market expectations. Earnings in line. The acquisition of Clinpal did not contribute materially to trading results. [SP=113 Cap=39m]
Microlise (SAAS) guides FY-Dec rev up 5%. Adj EBITDA lightly ahead of market expectations. [SP=120 Cap=139m]
Filtronic (FTC) $2m contract to be booked in calendar 2023. Warns FY23 below market expectations due to component shortages. [SP=12.5 Cap=27m]
Harworth (HWG) guides ERPA NDV towards the lower end of forecatst. Blames "market-driven outward yield movements in the valuation of the Investment Portfolio and more mature industrial & logistics major development sites". [SP=119 Cap=384m]
Kromek (KMK) £2.5m grants for two research programmes to further develop a low-dose molecular breast imaging. [SP=10 Cap=43m]
Venture Life (VLG) guides FY-Dec rev up 34%, slightly ahead of market expectations. Adj EBITDA t least in line. [SP=39.11 Cap=49m]
SigmaRoc (SRC) guides FY-Dec U/L EBITDA and EPS slightly ahead of current market consensus expectations of £99.5m and 7.7p. Outlook confident. [SP=57 Cap=364m]
MYCELX Technologies (MYX) guides FY-Dec rev c.$10m and loss c.$4m, above previous guidance due to strong Dec. [SP=33.94 Cap=10m]
LifeSafe (LIFS) guides FY-Dec rev £3.9m, above previous expectation of £3.5-3.8m. EBITDA slightly ahead of market expectations. [SP=40 Cap=9m]
accesso Technology (ACSO) guides FY-Dec rev at least $139m, ahead of its initial full year expectation. Current exp? [SP=808 Cap=335m]
MyHealthChecked (MHC) guides FY-Dec rev up 34%, above management expectations. EBITDA over $2m ($2.7m) - in line? [SP=1.4 Cap=11m]
The Property Franchise Group (TPFP) guides FY-Dec rev up 135. Profit head of market expectations. [SP=NA Cap=NA]
Belvoir (BLV) guides FY-Dec slightly ahead of mgmt expectations but warns FY23 slightly below 2022 and is expected to return to an upward trend in 2024. [SP=189 Cap=70m]
Somero (SOM) warns FY-Dec rev $134m, below previous guidance of $ 138.8m. Adj EBITDA c.$46m, below previous guidance of $47.7m [SP=430 Cap=240m]
NWF (NWF) H1-Nov rev and operating profit significantly ahead of the prior year and mgmt expectations. Nevertheless guides FY in line. [SP=228.24 Cap=113m]

In line: XLM, MAB1, GUS, CODE, RCDO, INS, TRX, RWI
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian